Phio Pharmaceuticals Corp. PHIOW 深 滬
等待開盤 08-21 09:30:00 美东时间
0.0232
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 0.0232
- 總市值 10.63万
- 52周最高 1.16
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.006
- 委 比 0.00%
- 總股本 458.09万
- 歷史最高 1.16
- 量 比 0
- 振 幅 0.00%
- 歷史最低 0.006
- 每 手 1
- 風險率 0.00%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Phio Pharmaceuticals adds dermatology expert to board
An announcement from Phio Pharmaceuticals ( ($PHIO) ) is now available. Effecti...
07-21 19:28
Phio Pharma To Discuss siRNA Oncology At Force Family Office Fireside Chat; INTASYL Program Positioned As Differentiated Immuno‑Oncology Strategy
Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will ...
06-25 19:19
Phio Pharma Q1 EPS $(0.34) Misses $(0.23) Estimate
Phio Pharma (NASDAQ:PHIO) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.23) by 47.83 percent. This is a 27.66 percent increase over losses of $(0.47) per share from the
05-08 04:51
Phio Pharma To Discuss Cancer Drug Progress In Upcoming Investor Chat, Highlights Early Results For Skin Cancer Treatment Ahead Of Event
Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today
04-13 19:14
Phio Pharmaceuticals Establishes New At-the-Market Equity Program
Phio Pharmaceuticals ( ($PHIO) ) has provided an announcement. On April 8, 2026...
04-09 05:15
